October 20, 2009 07:00 AM Eastern Daylight Time

TechnoVax Receives $2.9 Million Grant for Flu and Influenza Virus-Like Particle (VLP) Vaccine Program

TARRYTOWN, N.Y.--(BUSINESS WIRE)--TechnoVax, Inc., a biotechnology developer of novel vaccines was awarded a three-year $2.9 million SBIR phase II grant from the National Institutes of Health to further the development of its VLP-based, vaccine program.

“This award and recognition from the NIH emphasizes the importance of the VLP technology and this support will allow us to complete preclinical development and move into clinical testing of our influenza VLP vaccine candidates, including our H1N1 swine flu vaccine,” stated Dr. Jose Galarza, CEO of TechnoVax.

TechnoVax's Virus-Like Particle (VLP) technology is a novel way to produce vaccines against dangerous viruses because the VLPs contain no infectious material but are highly immunogenic. TechnoVax's VLP vaccine technology uses a cell-based system for production rather than the laborious chicken egg system. This technology can reduce production time, manufacturing steps and costs in a safer and controllable process, while increasing vaccine protection against multiple viruses.

Advantages of VLP’S

The VLP vaccine technology allows for the creation of structures that are immunologically and morphologically identical to a virus, but lack the genetic material required for both replication and infection. VLP-based vaccines, do not require chemical inactivation or attenuation as do some of the currently available vaccines. The technology can also be implemented for the production of vaccines directed against other infectious agents and cancer targets. This is one of the most advanced technologies in the vaccine field.

About TechnoVax Inc.

TechnoVax is a privately held biotechnology company based in Westchester County (New York) and specializes in vaccine development. The company aims to begin clinical trials within the next 18 months.

The company uses its unique and innovative VLP technology to produce mass market vaccines for infectious diseases such as influenza, respiratory syncytial virus (RSV), para-influenza virus (PIV) and other diseases such as HIV and cancer.

Pre-clinical tests have demonstrated complete efficacy against several flu viruses. TechnoVax's technology offers important advantages over current production methods such as faster development and scale-up manufacturing, cell-based production of greater safety and capacity, and ability to quickly respond to emerging new viruses while reducing time and cost. TechnoVax’s aims to address public health concerns; by increasing availability, while decreasing costs, of influenza vaccines. For more information, please visit: www.technovax.com.

Contacts

Technovax, Inc.
Hector Munoz, 914-345-2300 ext. 12
Vice President, Business Development and CFO
hmunoz@technovax.com